ArticleEuropean journal of translational myology2026
Analysis of the effects of dapagliflozin on cardiac myocyte injury markers and left ventricular diastolic function in heart failure patients with preserved ejection fraction after percutaneous coronary intervention.
Article in European journal of translational myology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to analyze the effects of Dapagliflozin on cardiac myocyte injury markers and left ventricular diastolic function in patients with Heart Failure with Preserved Ejection Fraction (HF-PEF) after Percutaneous Coronary Intervention (PCI). The study included 120 HF-PEF patients post-PCI treated at our hospital between May 2021 and May 2024. Patients were divided into two groups: conventional therapy (n=49) and Dapagliflozin plus conventional therapy (n=71). Serum Cardiac Troponin I (cTnI) and Serum Amyloid A (SAA) were measured. Left ventricular function was assessed by Ejection Fraction (EF) and the E/e' ratio. The incidence of Major Adverse Cardiovascular Events (MACE) was also recorded. After treatment, the Dapagliflozin group showed significantly lower cTnI and SAA levels compared to the conventional group (p<0.05). EF was higher and E/e' ratio was lower in the Dapagliflozin group (p<0.05). The incidence of MACE was reduced to 1.41% versus 12.24% in the conventional group (p<0.05). In conclusion, Dapagliflozin effectively reduces cardiac myocyte injury markers, improves left ventricular diastolic function, and lowers the incidence of MACE in HF-PEF patients after PCI, demonstrating significant translational benefits for cardiac muscle function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.